Mga Batayang Estadistika
| CIK | 1801834 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PainReform Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) In |
|
| August 19, 2025 |
Exhibit 99.1 PainReform/DeepSolar Accepted into NVIDIA Connect Program Acceptance to NVIDIA Connect Program offers access to unique tools for the development of DeepSolar’s nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy by up to 50% and optimize energy asset performance Tel Aviv – August 19, 2025 — PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSola |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) In |
|
| August 13, 2025 |
Exhibit 99.1 PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System Acquisition of Majority Equity Interest in LayerBio and its OcuRing™-K Technology Targets Growing Demand for ‘Dropless’ Solutions in Ophthalmic Surgery Tel Aviv – August 13, 2025 — PainReform Ltd. (N |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| July 10, 2025 |
Exhibit 10.1 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) made effective as of July 8, |
|
| July 10, 2025 |
Exhibit 99.1 PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio This Investment will add a differentiated ophthalmic platform, targeting an estimated 3 million annual U.S. cataract surgeries with long-acting, “dropless” pain and inflammation treatment Tel Aviv – July 10, 2025 — PainReform Ltd. (Nasdaq: PRFX) |
|
| May 9, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-286941 3,262,695 Ordinary Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to an aggregate of 3,262,695 or our ordinary shares, no par value per share, consisting of (i) 178,769 ordinary shares that were issued as part of the BladeRanger Transaction (as defined below), or the Shares, |
|
| May 7, 2025 |
PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 May 7, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PainReform Ltd. (CIK 0001801834) Registration Statement No. 333-286941 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PainReform Ltd. hereby requests acceleration of the effectiveness of the |
|
| May 7, 2025 |
Exhibit 99.1 PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar Projects Tel Aviv – May 7, 2025 — PainReform Ltd. (Nasdaq: PRFX) PainReform Ltd. (Nasdaq: PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The pr |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indic |
|
| May 2, 2025 |
Exhibit 3.1 PUBLIC COMPANY COMPANIES LAW, 5759 – 1999 A COMPANY LIMITED IN SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF PAINREFORM LTD (C.N 514056597) Index Part no. Article no. Subject Page Part One Preamble 1. Name of the company 4 2. Objectives of the company 4 3. Liability of shareholders 4 4. The Capital 4 Part Two General Provisions 5. Definitions and interpretations 4 6. Change of |
|
| May 2, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No. |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39481 PainReform Ltd. (Exact Name of Registrant as Specified in Its Charter) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-40614 PainReform LTD. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 7, 2025 |
Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Eyal Broder, certify that: 1. I have reviewed this annual report on Form 20-F of PainReform Ltd.: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 7, 2025 |
MILESTONE BASED ORDINARY SHARE PURCHASE WARRANT B PAINREFORM LTD. Exhibit 4.35 MILESTONE BASED ORDINARY SHARE PURCHASE WARRANT B PAINREFORM LTD. Warrant Shares: 1,087,565 Warrant Date: [ ], 2025 THIS MILESTONE BASED ORDINARY SHARE PURCHASE WARRANT B (the “Warrant”) certifies that, BLADERANGER LTD, registered under the laws of the State of Israel, Registration No. 515350932, a public company whose shares are listed for trading on TASE under the ticker “BLRN” or i |
|
| April 7, 2025 |
MILESTONE BASED ORDINARY SHARE PURCHASE WARRANT A PAINREFORM LTD. Exhibit 4.34 MILESTONE BASED ORDINARY SHARE PURCHASE WARRANT A PAINREFORM LTD. Warrant Shares: 1,087,565 Warrant Date: [ ], 2025 THIS MILESTONE BASED ORDINARY SHARE PURCHASE WARRANT A (the “Warrant”) certifies that, BLADERANGER LTD, registered under the laws of the State of Israel, Registration No. 515350932, a public company whose shares are listed for trading on TASE under the ticker “BLRN” or i |
|
| April 7, 2025 |
MILESTONE BASED PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 4.33 MILESTONE BASED PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: 470,463 Warrant Date: [ ], 2025 THIS MILESTONE BASED PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, BLADERANGER LTD, registered under the laws of the State of Israel, Registration No. 515350932, a public company whose shares are listed for trading |
|
| April 7, 2025 |
BUSINESS ACQUISITION AGREEMENT Exhibit 4.31 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed BUSINESS ACQUISITION AGREEMENT THIS BUSINESS ACQUISITION AGREEMENT (this “Agreement”), dated as of February 16, 2025, by and among P |
|
| April 7, 2025 |
Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of PainReform Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report |
|
| April 7, 2025 |
PAINREFORM LTD. INSIDER TRADING POLICY Exhibit 11.1 PAINREFORM LTD. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) sets forth the policy for directors, officers, employees, consultants and contractors of PainReform Ltd. and its subsidiaries (the “Company”) with respect to transactions in the Company’s securities or securities of certain other publicly traded companies while in possession of confidential information. |
|
| April 7, 2025 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 4.32 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: 223,792 Initial Exercise Date: [ ], 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, BLADERANGER LTD, registered under the laws of the State of Israel, Registration No. 515350932, a public company whose shares are listed for trading on TASE under the ticke |
|
| April 7, 2025 |
PainReform Provides Year-End Business Update Exhibit 99.1 PainReform Provides Year-End Business Update Tel Aviv, Israel – April 7, 2025 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of the DeepSolar activities, today provided a business update for the year ended December 31, 2024. Ehud Geller, Chairman and int |
|
| April 7, 2025 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of PainReform Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report |
|
| April 7, 2025 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ehud Geller, certify that: 1. I have reviewed this annual report on Form 20-F of PainReform Ltd.: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 7, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333- 254982, 333-282264, 333-283655, 333-276485, 333-277594) and Form S-8 (Nos. 333-257968 and 333-265902) of PainReform Ltd. of our report dated April 7, 2025, relating to the financial statements, which appears in this Form 20- |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-40614 PainReform LTD. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| March 5, 2025 |
Exhibit 99.1 PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Tel Aviv, Israel – March 5, 2025 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39481 PainReform Ltd. (Exact Name of Registrant as Specified in Its Charter) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive |
|
| February 27, 2025 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE EXTRAORDINARYGENERAL MEETING OF THE SHAREHOLDERS TO BE HELD ON APRIL 3, 2025 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Ehud Geller, the Interim Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned |
|
| February 27, 2025 |
NOTICE OF AN EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS TO BE HELD ON APRIL 3, 2025 Exhibit 99.1 NOTICE OF AN EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS TO BE HELD ON APRIL 3, 2025 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R T |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| February 18, 2025 |
Exhibit 99.1 PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potenti |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) I |
|
| January 2, 2025 |
PainReform Ltd. Up to $4,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-282264 PROSPECTUS SUPPLEMENT (To prospectus dated October 3, 2024) PainReform Ltd. Up to $4,000,000 Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated October 3, 2024, filed as a part of our registration statement on Form F-3 (File No. 333-282264), or the Registration Statement, as supplem |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| December 27, 2024 |
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 Exhibit 99.1 PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 Tel Aviv, Israel – December 26, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain |
|
| December 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-283655 511,963 Ordinary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 511,963 or our ordinary shares, no par value per share, consisting of (i) 494,650 ordinary shares issuable upon the exercise of common warrants to purchase ordinary shares that were issued as |
|
| December 11, 2024 |
PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 December 11, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PainReform Ltd. (CIK 0001801834) Registration Statement No. 333-283655 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PainReform Ltd. hereby requests acceleration of the effectiveness |
|
| December 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value |
|
| December 6, 2024 |
As filed with the Securities and Exchange Commission on December 6, 2024 As filed with the Securities and Exchange Commission on December 6, 2024 Registration No. |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 20, 2024 |
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial Exhibit 99.1 PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial Tel Aviv, Israel – November 20, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 14, 2024 |
PRFX / PainReform Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-prfx093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PAINREFORM LTD. (Name of Issuer) Ordinary shares, par value NIS 0.03 per share (Title of Class of Securities) M77798136 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 13, 2024 |
SC 13G/A 1 ea022071810-13ga1intrapain.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PainReform Ltd. (Name of Issuer) Ordinary shares, no par value per share (Title of Class of Securities) IL0011651580 (CUSIP Number) September 30, 2024 (Date of Event Which Requires |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-40614 PainReform LTD. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number: 001-41084 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive office |
|
| November 7, 2024 |
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement Exhibit 99.1 PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement ● This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market Tel Aviv, Israel., November 7, 2024, - PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focuse |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-40614 PainReform LTD. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) I |
|
| October 16, 2024 |
PainReform Ltd. Up to $1,350,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-282264 PROSPECTUS SUPPLEMENT (To prospectus dated October 3, 2024) PainReform Ltd. Up to $1,350,000 Ordinary Shares We have entered into an At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC, or Wainwright, dated October 16, 2024, or the Offering Agreement, relating to the sale of our ordinary shares, no par value per share, offer |
|
| October 16, 2024 |
AT THE MARKET OFFERING AGREEMENT Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT October 16, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: PainReform Ltd., a company formed under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this |
|
| October 10, 2024 |
NOTICE OF A SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 4, 2024 Exhibit 99.1 NOTICE OF A SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 4, 2024 To the shareholders of PainReform Ltd.: Notice is hereby given that a Special Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel on No |
|
| October 10, 2024 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 4, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Ehud Geller, the Interim Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) I |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) I |
|
| October 1, 2024 |
PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 October 1, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PainReform Ltd. (CIK 0001801834) Registration Statement No. 333-282264 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: PainReform Ltd. hereby requests acceleration of the effectiveness of |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| September 20, 2024 |
As filed with the Securities and Exchange Commission on September 20, 2024 As filed with the Securities and Exchange Commission on September 20, 2024 Registration No. |
|
| September 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of R |
|
| September 11, 2024 |
ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| September 11, 2024 |
Exhibit 10.1 PAINREFORM LTD. September 10, 2024 Holder of Warrants to Purchase Ordinary Shares: Re: Inducement Offer to Exercise Warrants Dear Holder: PainReform Ltd. (the "Company") is pleased to offer to you ("Holder", "you" or similar terminology) (i) the opportunity to receive new warrants to purchase ordinary shares of the Company, no par value per share (the "Ordinary Shares") and (ii) a red |
|
| September 11, 2024 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| September 10, 2024 |
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds Exhibit 99.1 PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) - PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certa |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| August 29, 2024 |
SC 13D/A 1 ea0212819-13da1liapurepain.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) PainReform Ltd. (Name of Issuer) Ordinary shares, no par value (Title of Class of Securities) M77798128 (CUSIP Number) August 28, 2024 (Date of Event which Requires Filing of this S |
|
| August 28, 2024 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 30, 2024 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 30, 2024 To the shareholders of PainReform Ltd.: Notice is hereby given that the Annual General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Br |
|
| August 28, 2024 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 30, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Ehud Geller, the Chairman of the Board of Directors and the Interim Chief Executive Officer of the Company, attorney, agent and proxy of the undersigned, with full power of substitution, t |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal e |
|
| August 27, 2024 |
Exhibit 3.1 PUBLIC COMPANY COMPANIES LAW, 5759 – 1999 A COMPANY LIMITED IN SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF PAINREFORM LTD (C.N 514056597) 1 Index Part no. Article no. Subject Page Part One Preamble 1. Name of the company 5 2. Objectives of the company 5 3. Liability of shareholders 5 4. The Capital 5 Part Two General Provisions 5 5. Definitions and interpretations 7 6. Chang |
|
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 POS AM 1 zk2431936.htm POS AM As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. 333-277594 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 ON FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PAINREFORM LTD. (Exact name of registrant as specified in its charter) State of Israel 28 |
|
| August 26, 2024 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 30, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Ehud Geller, the Chairman of the Board of Directors and the Interim Chief Executive Officer of the Company, attorney, agent and proxy of the undersigned, with full power of substitution, t |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) In |
|
| August 26, 2024 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 30, 2024 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 30, 2024 To the shareholders of PainReform Ltd.: Notice is hereby given that the Annual General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Br |
|
| August 26, 2024 |
EX-99.1 2 ea021237101ex99-1pain.htm JOINT FILING AGREEMENT BY AND AMONG L.I.A. PURE CAPITAL LTD. AND KFIR SILBERMAN, DATED AUGUST 26, 2024 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional ame |
|
| August 26, 2024 |
PRFX / PainReform Ltd. / L.I.A. Pure Capital Ltd - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 PainReform Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.30 per share (Title of Class of Securities) M77798128 (CUSIP Number) August 22, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule |
|
| August 15, 2024 |
Exhibit 99.3 PainReform Provides Business Update for the Second Quarter of 2024 Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late 2024 New highly scalable manufacturing process expected to significantly enhance future commercialization efforts Tel Aviv, Israel – August 15, 2024 – PainReform Ltd. (Nasda |
|
| August 15, 2024 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ (Deficit) Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-12 PAINREFORM LTD. CONDENSED BALANCE SHE |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) In |
|
| August 15, 2024 |
Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this Form 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) In |
|
| July 9, 2024 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 13, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Ehud Geller, the Interim Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned a |
|
| July 9, 2024 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 13, 2024 Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 13, 2024 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel(Address of principal executive offices) Indic |
|
| June 26, 2024 |
Exhibit 99.1 PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110 Top line data to be reported in the second half of 2024 Tel Aviv, Israel – June 26, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major mil |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indic |
|
| May 31, 2024 |
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification Tel Aviv, Israel, May 31, 2024 — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indica |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indic |
|
| May 15, 2024 |
Exhibit 99.3 PainReform Provides Business Update for the First Quarter of 2024 Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 Tel Aviv, Israel – May 15, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the refor |
|
| May 15, 2024 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-10 PAINREFORM LTD. CONDENSED BALANCE SHEETS (Unau |
|
| May 15, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accou |
|
| April 24, 2024 |
PRFX / PainReform Ltd. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PainReform Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.30 per share (Title of Class of Securities) IL0011651580 (CUSIP Number) April 15, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| April 24, 2024 |
EX-1 2 ea020459101ex99-1pain.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreeme |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 17, 2024 |
Exhibit 10.5 April 15, 2024 Holder of Warrants to Purchase Ordinary Shares set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form F-1 (File No. 333-277594) on or about the date hereof (the “Offering”) by PainReform Ltd. (the “Company”) of its ordinary shares, nominal value NIS 0.3 per share (“Ordinary Shares”), and/or |
|
| April 17, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276485 PROSPECTUS SUPPLEMENT (To Prospectus dated January 19, 2024) 968,545 Ordinary Shares This prospectus supplement, or the Supplement, modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus originally filed with the Securities and Exchange Commission, or the SEC |
|
| April 17, 2024 |
PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-277594 447,500 Ordinary Shares 4,552,500 Pre-Funded Warrants to Purchase up to an aggregate of 4,552,500 Ordinary Shares (and up to an aggregate of 4,552,500 Ordinary Shares issuable upon the exercise of the Pre-Funded Warrants) 5,000,000 Common Warrants to Purchase up to an aggregate of 5,000,000 Ordinary Shares (and up to an aggreg |
|
| April 16, 2024 |
PainReform Announces Pricing of $4 Million Public Offering Exhibit 99.1 PainReform Announces Pricing of $4 Million Public Offering TEL AVIV, Israel, April 16, 2024 (GLOBE NEWSWIRE) - PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the pricing of a public offering of an aggregate of 5,000,000 of the Company’s ordinary |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 15, 2024 |
Exhibit 3.1 PUBLIC COMPANY COMPANIES LAW, 5759 – 1999 A COMPANY LIMITED IN SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF PAINREFORM LTD (C.N 514056597) Index Part no. Article no. Subject Page Part One Preamble 1. Name of the company 2 2. Objectives of the company 2 3. Liability of shareholders 2 4. The Capital 2 Part Two General Provisions 5. Definitions and interpretations 2 6. Change of |
|
| April 15, 2024 |
ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 4.3 ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: Initial Exercise Date: , 2024 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| April 15, 2024 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 4.4 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: Initial Exercise Date: , 2024 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| April 15, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 4.2 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| April 15, 2024 |
Exhibit 10.23 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between PainReform Ltd., a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| April 15, 2024 |
As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No. |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 9, 2024 |
Exhibit 99.1 PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions Tel Aviv, Israel – April 9, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking results from |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| April 2, 2024 |
Exhibit 99.1 PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy Remains on track to announce top-line data by mid-2024 Tel Aviv, Israel – April 2, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| March 7, 2024 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS HELD ON APRIL 8, 2024 Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS HELD ON APRIL 8, 2024 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei |
|
| March 7, 2024 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 8, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Ilan Hadar , Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the ordinar |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St. Tel Aviv, Israel 6744316 Tel: +972 3 7177051 (Address of principal ex |
|
| March 1, 2024 |
Exhibit 99.1 PainReform Provides Year-End Business Update Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 Tel Aviv, Israel – March 1, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registrat |
|
| February 29, 2024 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ilan Hadar, certify that: 1. I have reviewed this annual report on Form 20-F of PainReform Ltd.: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| February 29, 2024 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of PainReform Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report |
|
| February 29, 2024 |
Exhibit 97.1 PainReform Ltd. Executive Officer Clawback Policy Approved by the Compensation Committee of the Board of Directors on November 27, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of PainReform Ltd. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erron |
|
| February 29, 2024 |
Exhibit 1.1 PUBLIC COMPANY COMPANIES LAW, 5759 – 1999 A COMPANY LIMITED IN SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF PAINREFORM LTD (C.N 514056597) Index Part no. Article no. Subject Page Part One Preamble 1. Name of the company 4 2. Objectives of the company 4 3. Liability of shareholders 4 4. The Capital 4 Part Two General Provisions 5. Definitions and interpretations 4 6. Change of |
|
| February 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-259318, 333-254982 and 333-276485) and Form S-8 (Nos. 333-257968 and 333-265902) of PainReform Ltd. of our report dated February 29, 2024, relating to the financial statements, which appears in this Form 20-F. /s/Kesselman & |
|
| February 15, 2024 |
PRFX / PainReform Ltd. / GELLER EHUD - SC 13G/A Passive Investment SC 13G/A 1 zk2431000.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* PainReform Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.03 per share (Title of Class of Securities) M77798128 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
PRFX / PainReform Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-prfx123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PAINREFORM LTD. (Name of Issuer) Ordinary shares, par value NIS 0.03 per share (Title of Class of Securities) M77798128 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| January 23, 2024 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Statement on Schedule 13G filed herewith, and any amendments thereto filed hereafter by any of the undersigned parties, relating to the ordinary shares, par value NIS 0.30 per share, of PainReform Ltd., is being (and will be, in the case of amendments hereto) filed jointly with the Securi |
|
| January 23, 2024 |
PRFX / PainReform Ltd. / XT Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2430799.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* PainReform Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.30 per share (Title of Class of Securities) M77798128 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 19, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276485 PROSPECTUS 968,545 Ordinary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 968,545 ordinary shares, par value NIS 0.30 per share, of PainReform Ltd. issuable upon the exercise of warrants, as further described below under “Prospectus Summary — Recent Devel |
|
| January 18, 2024 |
PainReform Ltd. 4 Bruria St., Tel Aviv 6745442, Israel PainReform Ltd. 4 Bruria St., Tel Aviv 6745442, Israel January 18, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: PainReform Ltd. Registration Statement on Form F-3 File No. 333-276485 Ladies and Gentlemen: PainReform Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Regis |
|
| January 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, par value NI |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. |
|
| January 3, 2024 |
Exhibit 99.1 PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading Tel Aviv, Israel – January 3, 2024 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) I |
|
| December 27, 2023 |
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Exhibit 99.1 PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds Tel Aviv, Israel – December 26, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a definitive agreement for the immediate exercise of c |
|
| December 27, 2023 |
Exhibit 10.1 PAINREFORM LTD. December 26, 2023 Holder of Warrants to Purchase Ordinary Shares Issued in July 2023: Re: Inducement Offer to Exercise Warrants Issued in July 2023 Dear Holder: PainReform Ltd. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase ordinary shares of the Company, par value NIS 0.30 per |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| December 27, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-274220 PROSPECTUS SUPPLEMENT (To Prospectus dated September 1, 2023) 467,896 Ordinary Shares This prospectus supplement, or the Supplement, modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus originally filed with the Securities and Exchange Commission, or the SE |
|
| December 27, 2023 |
ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 27, 2023 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 15, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this Form 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our |
|
| November 15, 2023 |
Exhibit 99.3 ha PainReform Provides Business Update for the Third Quarter of 2023 Reports progress on enrollment of first patients for second part of Phase 3 clinical trial in bunionectomy Tel Aviv, Israel – November 15, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 15, 2023 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5-F-6 Notes to Condensed Financial Statements F-7 - F-13 PAINREFORM LTD. CONDENSED BALANCE SHEE |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| September 11, 2023 |
Exhibit 99.1 PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 Tel Aviv, Israel – September 11, 2023 – PainReform Ltd. (Nasdaq: PRFX) |
|
| September 5, 2023 |
PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-274220 467,896 Ordinary Shares PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-274220 467,896 Ordinary Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to an aggregate of 467,896 ordinary shares, par value NIS 0.30 per share of PainReform Ltd., consisting of (i) 301,230 ordinary shares issuable upon the exercise of warrants originally issued in a priv |
|
| August 30, 2023 |
PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316 August 30, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: PainReform Ltd. (CIK 0001801834) Registration Statement No. 333-274220 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: PainReform Ltd. (the “Registrant”) hereby requests acceleration of t |
|
| August 25, 2023 |
As filed with the Securities and Exchange Commission on August 25, 2023 As filed with the Securities and Exchange Commission on August 25, 2023 Registration No. |
|
| August 25, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, par value NI |
|
| August 10, 2023 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. d |
|
| August 10, 2023 |
Exhibit 99.3 ha PainReform Provides Business Update for the Second Quarter of 2023 Targeting to commence second part of Phase 3 clinical trial in bunionectomy during the fourth quarter of 2023 Tel Aviv, Israel – August 10, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics |
|
| August 10, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this Form 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) In |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| July 19, 2023 |
PainReform Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 PainReform Regains Compliance with Nasdaq Continued Listing Requirements Tel Aviv, Israel – July 19, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received notice from Nasdaq on July 18, 2023, indicating that it has regai |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| July 18, 2023 |
PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated September 13, 2021) Registration No. |
|
| July 18, 2023 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT July 14, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), PainReform Ltd., a company formed under the laws of the State of Israel (the “Company”), hereby agrees to sell up to an aggregate of $1,499,994.00 of registered and unregistered securi |
|
| July 18, 2023 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.3 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: Initial Exercise Date: July 18, 2023 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| July 18, 2023 |
ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 18, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2023, between PainReform Ltd., a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to t |
|
| July 14, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 12, 2023, between PainReform Ltd., a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to t |
|
| July 14, 2023 |
PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated September 13, 2021) Registration No. |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| July 14, 2023 |
/s/Doron, Tikotzky, Kantor, Gutman, Nass, Amit Gross & Co Exhibit 5.1 July 14, 2023 Painreform Ltd. 65 Yigal Alon Street, P.O. Box 68, Tel Aviv-Yafo 6744316, Israel Dear Sir and Madam: We have acted as Israeli counsel to Painreform Ltd. (the “Company”), a company organized under the laws of the State of Israel in connection with the Securities Purchase Agreement, dated July 12, 2023 (the “Agreement”, which definition includes all listed exhibits and sche |
|
| July 14, 2023 |
Exhibit 5.2 July 14, 2023 PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel Re: Prospectus Supplement Pursuant to Rule 424(b)(5) Ladies and Gentlemen: We have acted as U.S. counsel to PainReform Ltd., an Israeli company (the “Company”), in connection with the Securities Purchase Agreement, dated July 12, 2023 (the “Securities Purchase Agreement”, which definition includes all listed exhibits and |
|
| July 14, 2023 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.3 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Warrant Shares: Initial Exercise Date: [ ], 2023 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| July 14, 2023 |
ORDINARY SHARE PURCHASE WARRANT PAINREFORM LTD. Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 14, 2023 |
Exhibit 99.1 PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement Tel Aviv, Israel – July 14, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into a definitive agreement for the pur |
|
| July 14, 2023 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT July 12, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), PainReform Ltd., a company formed under the laws of the State of Israel (the “Company”), hereby agrees to sell up to an aggregate of $2,711,070 of registered and unregistered securitie |
|
| July 12, 2023 |
Exhibit 99.1 PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement Tel Aviv, Israel – July 12, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into a definitive agreement for the pur |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| June 7, 2023 |
Exhibit 99.1 PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Tel Aviv, Israel – June 7, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a regulatory update on the s |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indic |
|
| May 18, 2023 |
Exhibit 99.1 PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Reports excellent compliance with FDA safety requirements in the first part of its Phase III with 15 patients Tel Aviv, Israel – May 18, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty p |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indic |
|
| May 15, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accou |
|
| May 15, 2023 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. |
|
| May 15, 2023 |
Exhibit 99.3 PainReform Provides Business Update for the First Quarter of 2023 Reports Progress on Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Tel Aviv, Israel – May 15, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St. Tel Aviv, 67444316, Israel (Address of principal ex |
|
| May 4, 2023 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 8, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Ilan Hadar , Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the ordinary shares |
|
| May 4, 2023 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 8, 2023 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 8, 2023 To the shareholders of PainReform Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Brak |
|
| May 3, 2023 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 1, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Ilan Hadar , Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the ordinary shares |
|
| May 3, 2023 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 1, 2023 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 1, 2023 To the shareholders of PainReform Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Brak |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St. Tel Aviv, 67444316, Israel (Address of principal executive offices) Ind |
|
| May 1, 2023 |
Exhibit 99.1 PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Reports Solid Safety Profile of PRF-110 and No Serious Adverse Events among First 15 Patients Tel Aviv, Israel – May 1, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused o |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indic |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| March 28, 2023 |
Exhibit 99.1 PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery First 15 patients administered PRF-110 intra-operatively Tel Aviv, Israel – March 28, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced comp |
|
| March 16, 2023 |
Exhibit 99.1 PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy Tel Aviv, Israel – March 16, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022. Il |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| March 15, 2023 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of PainReform Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, |
|
| March 15, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement on Form F-3 (No. 333-259318 and 333-254982) and Form S-8 (No. 333-257968 and 333-265902) of our report dated March 18, 2021, relating to the financial statements of PainReform Ltd. appearing in the annual report on Form 20-F of PainReform Ltd. for the year en |
|
| March 15, 2023 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Ilan Hadar, certify that: 1. I have reviewed this annual report on Form 20-F of PainReform Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 15, 2023 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Ilan Hadar, certify that: 1. I have reviewed this annual report on Form 20-F of PainReform Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 15, 2023 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of PainReform Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, |
|
| March 15, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-259318 and 333-254982) and Form S-8 (Nos. 333-257968 and 333-265902) of PainReform Ltd. of our report dated March 14, 2023, relating to the financial statements, which appears in this Form 20-F. /s/ Kesselman & Kesselman Cert |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Ind |
|
| March 14, 2023 |
Exhibit 99.1 PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Initial pharmacokinetic data on first 15 patients expected in May 2023 Tel Aviv, Israel – March 14, 2023 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of establishe |
|
| March 2, 2023 |
PRFX / PainReform Ltd / GELLER EHUD - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* PainReform Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.03 per share (Title of Class of Securities) M77798102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2329134.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of princ |
|
| February 7, 2023 |
Exhibit 99.1 PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement Tel Aviv, Israel – November 15, 2022 – PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced today that on February 7, 2023, it received a letter |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 25, 2022 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 29, 2022 Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 29, 2022 To the shareholders of PainReform Ltd.: Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 65 Yigal Alon St. Tel Aviv, 67444316, Israel (Address of principal executive offices |
|
| November 25, 2022 |
Exhibit 99.2 PainReform Ltd. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 29, 2022 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Mr. Ilan Hadar , Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the ordinary s |
|
| November 15, 2022 |
Exhibit 99.1 Phar PainReform Provides Business Update for the Third Quarter of 2022 Implements Technology Improvements Related to PRF-110 Manufacturing Process Ahead of Planned Phase 3 Clinical Trial in Bunionectomy Tel Aviv, Israel ? November 15, 2022 ? PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) |
|
| November 14, 2022 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022, U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022, UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders’ Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS |
|
| November 14, 2022 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accou |
|
| November 14, 2022 |
6-K 1 zk2228694.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of princ |
|
| November 8, 2022 |
PainReform Provides Further Update on Manufacturing of PRF-110 Exhibit 99.1 PainReform Provides Further Update on Manufacturing of PRF-110 TEL AVIV, Israel, Nov. 8, 2022 (GLOBE NEWSWIRE) - PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a further update related to the manufacturing process of clinical batches for PRF-110. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 4 Bruria St. Tel Aviv, 6745442 Israel (Address of principal executive offices) Indic |
|
| October 4, 2022 |
Exhibit 99.1 PainReform Provides PRF-110 Manufacturing Update Completed tech transfer to CMO resulting in new process improvements On track to commence Phase 3 clinical trial in bunionectomy in November 2022 Tel Aviv, Israel ? October 4, 2022 ? PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of establish |
|
| October 4, 2022 |
6-K 1 zk2228535.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 4 Bruria St. Tel Aviv, 6745442 Israel (Address of principal e |
|
| August 16, 2022 |
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification Tel Aviv, Israel, August 16, 2022 ? PainReform Ltd. (Nasdaq: PRFX) (?PainReform? or the ?Company?), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the ?Letter?), ind |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 4 Bruria St. Tel Aviv, 6745442 Israel (Address of principal executive offices) Indicat |
|
| August 15, 2022 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders? Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS (UNAUD |
|
| August 15, 2022 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this Form 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 4 Bruria St. Tel Aviv, 6745442 Israel (Address of principal executive offices) Indicat |
|
| August 15, 2022 |
Exhibit 99.3 PainReform Provides Business Update for the Second Quarter of 2022 On track to commence Phase 3 clinical trial in bunionectomy in the fourth quarter of 2022 Completes tech transfer to CMO for manufacturing of clinical batches Tel Aviv, Israel ? August 15, 2022 ? PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indi |
|
| July 29, 2022 |
Exhibit 99.1 Investor Presentation July 2022 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be identified by the use of forward - looking words such as ?believe?, ?expect?, ?intend?, ?plan?, ?may?, ?should?, ?c |
|
| June 29, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) PainReform Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, par value NIS 0 |
|
| June 29, 2022 |
As filed with the Securities and Exchange Commission on June 29, 2022 Registration No. |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant?s name into English) 4 Bruria St. Tel Aviv, 6745442 Israel (Address of principal executive offices) Indicate b |
|
| May 17, 2022 |
Exhibit 99.1 PainReform Provides Business Update for the First Quarter of 2022 Reports successful batch manufacturing of PRF-110 and continued progress towards commencing Phase 3 clinical trials in the second half of 2022 Tel Aviv, Israel ? May 17, 2022 ? PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation o |
|
| May 16, 2022 |
Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accou |
|
| May 16, 2022 |
6-K 1 zk2227824.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant’s name into English) 4 Bruria St. Tel Aviv, 6745442 Israel (Address of principal execu |
|
| May 16, 2022 |
PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statements of Changes in Shareholders? Equity F-4 Condensed Statements of Cash Flows F-5 Notes to Condensed Financial Statements F-6 - F-11 PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. |
|
| March 17, 2022 |
Exhibit 99.1 PainReform Provides Year-End Business Update; On track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 Tel Aviv, Israel ? March 17, 2022 ? PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a b |
